Semnur Pharmaceuticals, Inc.
SMNR
$9.00
-$10.00-52.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.13% | 62.75% | 81.77% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.43% | -5.31% | 43.82% | -- | -- |
| Operating Income | 16.43% | 5.31% | -43.82% | -- | -- |
| Income Before Tax | 16.43% | 5.31% | -43.82% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.43% | 5.31% | -43.82% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.43% | 5.31% | -43.82% | -- | -- |
| EBIT | 16.43% | 5.31% | -43.82% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 16.13% | 5.12% | -43.63% | -- | -- |
| Normalized Basic EPS | 15.52% | 4.43% | -46.03% | -- | -- |
| EPS Diluted | 16.13% | 5.12% | -43.63% | -- | -- |
| Normalized Diluted EPS | 15.52% | 4.43% | -46.03% | -- | -- |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | -- | -- |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |